AMGEN: HOOPER Amgen appointed Anthony (Tony) Hooper, executive vice president, Global Commercial Operations. Hooper will report to Robert A. Bradway, president and chief operating officer, and will be responsible for the company’s global commercial operations. Hooper, 56, joins Amgen after 16 years at Bristol-Myers Squibb Company (BMS) where he was most recently senior vice president, Commercial Operations and president, United States, Japan and Intercontinental.
BMS: CAFORIO, BANCROFT, CAZALA Bristol-Myers Squibb announced a series of senior management changes following Hooper’s departure. Giovanni Caforio has been promoted to president, U.S. Pharmaceuticals. Caforio was most recently senior vice president, Oncology and Immunology Global Commercialization. In addition, Charles Bancroft and Beatrice Cazala were appointed Executive Vice Presidents of Bristol-Myers Squibb. Bancroft will add to his role of Chief Financial Officer operational responsibility for the pharmaceutical business in Latin America, Middle East, Africa, Canada, Japan and several other countries in the Pacific Rim. Cazala will add responsibility for global policy to her role leading Global Commercialization, Europe and Emerging Markets.
MICROMASS: STALLINGS MicroMass appointed Molly Stallings to group account supervisor. Stallings, who has worked on both the client and agency sides of the business, was previously North America product director, facial aesthetics for Mentor Worldwide.
PANMIRA: KUMAR Panmira announced the appointment of Hari Kumar, PhD, as chief executive officer. Until recently, Dr. Kumar served as chief business officer of Amira Pharmaceuticals.
IMMUNE DESIGN: CIPRIANI Guy F. Cipriani, MBA will be joining Immune Design as its new chief business officer. Cipriani has more than 12 years of pharmaceutical and biotechnology industry experience.
CONVERSATION: KELLAM and LIN Conversation announced the promotions of Myles Kellam and Mimi Lin. Myles Kellam will move from the agency’s managing director position to chief strategy officer, and Mimi Lin will replace Kellam as managing director. Lin was previously the director of business operations at the agency.
ALSIC: HARRISON, DUNN, HART, KNUTH and MOHLER The American Life Sciences Innovation Council (ALSIC) announced its board of directors: William Harrison, the president and chief executive officer of VIDA Sciences; Dr. Joseph Dunn, chief executive officer and director of research at OmniPharm Research International; H. Dean Hart, chief commercial officer of NanoInk; Steve Knuth, chief executive officer at Public Affairs Company; and David Mohler, a leading public policy attorney and consultant to the life sciences industry.
REATA: AUDHYA, MALONE, NOLAN and ROUSE At Reata Pharmaceuticals, a significant expansion of the management team was made to support the company’s lead program, bardoxolone methyl, and to continue advancing its earlier-stage pipeline. Joining the company are the following executives: Paul Audhya, MD, as vice president of development and chief medical officer; Hilary Malone, PhD, as vice president and chief regulatory and compliance officer; Sean Nolan as vice president and chief commercial officer; and Jim Rouse as vice president and chief information officer.
INSPIRATION: BUTLER, GRIFFITH Inspiration Biopharmaceutical announced the appointment of John P. Butler as chief executive officer. Butler replaces Michael Griffith, Ph.D., who has assumed the role of chief scientific officer and is retaining the title of President at Inspiration. Butler brings to Inspiration more than 20 years of experience commercializing innovative therapies.
ONCOBIOLOGICS: CANUTE Oncobiologics appointed Scott Canute, a former president at both Eli Lilly and Genzyme, to its board of directors. Most recently, Canute spent more than a year as president of global manufacturing and corporate operations for Genzyme.
CARDIAC DIMENSIONS: BOUKNIGHT Sales and marketing executive Omari V. Bouknight was named vice president of sales and marketing at Cardiac Dimensions. Most recently, Bouknight served as business unit director, chronic circulatory support for Thoratec.
LILLY: RICKS, CROWE, and AZAR Eli Lilly announced key appointments due to the December 31 retirements of longtime senior leaders, Bryce D. Carmine and Frank Deane, PhD. Dave Ricks, president of Lilly USA, is being promoted to succeed Carmine as senior vice president and president of Lilly Bio-Medicines; Maria Crowe, senior vice president for global drug product manufacturing, is being promoted to succeed Deane as president of manufacturing operations; and Alex Azar, following Ricks promotion, is being promoted to president of Lilly USA.
PDI: MELILLO PDI announced the appointment of Gerald R. Melillo, Jr. as senior vice president of business development. Melillo was most recently general manager of the southeast operating unit for Novartis. From 2004 to 2008 at Novartis, he was vice president of the ABGIU business franchise.
VIRTUAL RADIOLOGIC: BASU Virtual Radiologic announced that Pat Basu, MD, MBA, will be joining its executive and radiologist leadership teams as chief medical officer. Dr. Basu has just completed a one-year term as a White House Fellow. Previously, Dr. Basu held faculty appointments at Stanford University where he also served as course director of health policy, finance and economics.
CUMBERLAND: GREENE Rick S. Greene was named chief financial officer of Cumberland Pharmaceuticals. He has served as interim vice president, finance & accounting since April of this year; previously, he served as chief financial officer at Surgical Alliance Corporation and director of financial operations at Phycor. —Lauren Genovesi